慢性硬膜下血肿钻孔引流术后急性颅内再出血的原因及外科治疗

注册号:

Registration number:

ChiCTR2600121887 

最近更新日期:

Date of Last Refreshed on:

2026-04-07 09:15:23 

注册时间:

Date of Registration:

2026-04-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

慢性硬膜下血肿钻孔引流术后急性颅内再出血的原因及外科治疗

Public title:

The cause and surgical treatment for postoperative acute intracranial hemorrhage of burr hole drainage of chronic subdural hematoma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

慢性硬膜下血肿术后颅内急性再出血原因及手术

Scientific title:

Thecause andsurgical treatment for postoperative acute intracranial hemorrhage of burr holedrainage of chronic subdural hematoma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张小林 

研究负责人:

张小林 

Applicant:

Zhang xiaolin 

Study leader:

Zhang xiaolin 

申请注册联系人电话:

Applicant telephone:

+86 574 86860692

研究负责人电话:

Study leader's
telephone:

+86 574 8677 6590

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

syzxlin@qq.com

研究负责人电子邮件:

Study leader's E-mail:

syzxlin@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

宁波市北仑区庐山东路1288号

研究负责人通讯地址:

宁波市北仑区庐山东路1288号

Applicant address:

No. 1288 East Lushan Road, Beilun District, Ningbo City, Zhejiang Province,China

Study leader's address:

No. 1288 East Lushan Road, Beilun District, Ningbo City, Zhejiang Province,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

宁波市北仑区人民医院

Applicant's institution:

Ningbo Beilun People’s Hospital

研究负责人所在单位:

宁波市北仑区人民医院

Affiliation of the Leader:

Ningbo Beilun People’s Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

宁波市北仑区人民医院伦审2026研第004号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁波市北仑区人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Ningbo Beilun People’s Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-01-26 00:00:00

伦理委员会联系人:

汪碧亚

Contact Name of the ethic committee:

Wang Biya

伦理委员会联系地址:

宁波市北仑区庐山东路1288号

Contact Address of the ethic committee:

No. 1288 East Lushan Road, Beilun District, Ningbo City, Zhejiang Province,China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 574 86776056

伦理委员会联系人邮箱:

Contact email of the ethic committee:

28148538@qq.com

研究实施负责(组长)单位:

宁波市北仑区人民医院

Primary sponsor:

Ningbo Beilun People’s Hospital

研究实施负责(组长)单位地址:

宁波市北仑区庐山东路1288号

Primary sponsor's address:

No. 1288 East Lushan Road, Beilun District, Ningbo City, Zhejiang Province,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市北仑区人民医院

具体地址:

宁波市北仑区庐山东路1288号

Institution
hospital:

Ningbo Beilun People’s Hospital

Address:

No. 1288 East Lushan Road, Beilun District, Ningbo City, Zhejiang Province,China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

self-raised funds

研究疾病:

慢性硬膜下血肿  

Target disease:

chronic subdural hematoma

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

分析慢性硬膜下血肿术后颅内急性再出血病因,提出预防及治疗措施,提高此类患者的救治成功率。  

Objectives of Study:

Analysis of the Etiology of Acute Intracranial Rebleeding after Chronic Subdural Hematoma Surgery, and Proposals of Preventive and Therapeutic Measures to Improve the Treatment Success Rate for Such Patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

Exclusion criteria:

None

研究实施时间:

Study execute time:

From 2026-04-08 00:00:00 To 2026-04-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-08 00:00:00 To 2026-04-14 00:00:00

干预措施:

Interventions:

组别:

慢性硬膜下血肿钻孔引流术后颅内急性再出血

样本量:

469

Group:

Acute Intracranial Rebleeding after Burr Hole Drainage for Chronic Subdural Hematoma

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市北仑区人民医院 

单位级别:

三级 

Institution
hospital:

Ningbo Beilun People’s Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

再出血类型及原因

指标类型:

主要指标

Outcome:

GOS

Type:

Primary indicator

测量时间点:

钻孔引流术后

测量方法:

CT

Measure time point of outcome:

After Burr Hole Drainage

Measure method:

CT

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采集的临床资料:住院号,性别,年龄,钻孔引流术日期,术后发生急性颅内再出血时间,引流管拔除日期,颅脑 CT 片,二次手术方式,二次术后 3 月 GOS 评分。 受试者的保护措施:1.隐私与数据脱敏:提取的病历数据需进行去标识化处理,删除姓名、身份证号、住院号等直接标识符,仅保留研究所需的疾病、治疗、预后等核心信息;数据存储需采用加密系统,仅限研究人员授权访问,严禁以任何形式泄露受试者个人信息;2. 数据安全与管理:建立规范的数据管理台账,明确数据采集、录入、分析的责任人;原始病历资料需由医院病案室统一保管,研究人员仅能在授权范围内调取;研究结束后,脱敏数据需按规定存档,涉及个人隐私的原始数据需及时销毁或封存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Collected Clinical Data​​Hospital number​Gender​Age​Date of burr hole drainage​Time of acute intracranial rebleeding after surgery​Date of drainage tube removal​Cranial CT scans​Secondary surgical method​GOS score (Glasgow Outcome Scale) at 3 months after the secondary surgery​Subject Protection Measures​Privacy Protection and Data Desensitization​De-identification of extracted medical record data: Remove direct identifiers such as name, ID number, and hospital number, retaining only core information required for the study (e.g., disease status, treatment details, prognosis).​Encrypted data storage: Adopt an encryption system for data storage, with access restricted to authorized researchers only. Disclosure of subjects' personal information in any form is strictly prohibited.​Data Security and Management​Establish a standardized data management account book to clarify the responsible persons for data collection, entry, and analysis.​Original medical records shall be uniformly stored by the hospital's medical record department, and researchers may only retrieve data within the authorized scope.​After the completion of the study, desensitized data shall be archived in accordance with relevant regulations. Original data involving personal privacy shall be promptly destroyed or sealed.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-07 09:15:15